Application of α-ketoglutaric acid in the preparation of drugs that enhance the susceptibility of aquatic pathogens to florfenicol

The combined application of α-ketoglutarate and florfenicol has solved the problem of limited applicability of synergists in aquaculture, improved the bactericidal effect of florfenicol on aquatic pathogens, reduced drug use and residues, and promoted the sustainable development of aquaculture.

CN122075462APending Publication Date: 2026-05-26JINAN UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202610179818.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-02-09
Publication Date
2026-05-26

AI Technical Summary

Technical Problem

Existing synergists have limited applicability in aquaculture, their synergistic effects are unclear, and some antibiotics have been banned or have developed resistance issues, leading to reduced antibiotic efficacy and increased environmental pollution in aquaculture.

Method used

The use of α-ketoglutaric acid or its pharmaceutically acceptable salt in combination with florfenicol can improve the sensitivity of aquatic pathogens to florfenicol and enhance its bactericidal effect.

Benefits of technology

It significantly improves the bactericidal effect of florfenicol on aquatic pathogens, reduces antibiotic use, lowers drug residues, and improves the survival rate and health status of aquatic organisms.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122075462A_ABST
    Figure CN122075462A_ABST
Patent Text Reader

Abstract

This invention belongs to the field of biomedical technology, specifically relating to the application of α-ketoglutarate in the preparation of drugs that enhance the sensitivity of aquatic pathogens to florfenicol. This invention is the first to discover that α-ketoglutarate can significantly enhance the bactericidal effect of florfenicol against aquatic pathogens. Combined injection of α-ketoglutarate and florfenicol can reduce the number of bacteria in the liver and spleen of aquatic organisms, including fish, infected with aquatic pathogens, thus reducing damage to the organs and tissues of fish and other aquatic organisms and improving their survival rate. Therefore, α-ketoglutarate can be used as a synergist for florfenicol. Its combined application in the preparation of compound antibacterial agents can improve the efficacy of aquatic antibacterial drugs, significantly reduce the dosage of antibacterial drugs, and consequently reduce side effects and drug residues. This has significant application value and importance in the production and development of drugs against aquatic pathogens.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biomedical technology, specifically relating to the application of α-ketoglutarate in the preparation of drugs that enhance the sensitivity of aquatic pathogens to florfenicol. Background Technology

[0002] Vibrio alginolyticus ( Vibrio alginolyticus , V. alginolyticus Vibrio alginolyticus is a common aquatic pathogen widely distributed in both seawater and freshwater environments, exhibiting strong pathogenicity. With the long-term and widespread use of antibiotics in aquaculture, a large number of drug-resistant Vibrio bacteria have emerged in the environment, especially the newly discovered carbapenem-resistant Vibrio alginolyticus, posing a potential threat to aquaculture safety and human health. Carbapenem antibiotics (such as imipenem, meropenem, and ertapenem), as last-line drugs for the clinical treatment of severe bacterial infections, have not yet been approved for use in aquaculture. However, the phenomenon of forced overuse of other antibiotics due to escalating drug resistance problems is becoming increasingly common in aquaculture, which not only accelerates the evolution of bacterial resistance but also leads to increasingly prominent problems of drug residues and environmental pollution.

[0003] Of the antibiotics once used in aquaculture, chloramphenicol has been banned in most countries worldwide (including China) due to serious food safety risks. While kanamycin, gentamicin, and streptomycin were historically or legally permitted, they are no longer first-line drugs given the current prevalence of antibiotic resistance and increasingly stringent regulations. Long-term or excessive use of these antibiotics can also induce bacterial resistance and potentially threaten human health through the food chain. Therefore, maintaining or restoring the efficacy of antibiotics without increasing dosage has become a critical issue that urgently needs to be addressed in the prevention and control of diseases in aquaculture.

[0004] Against this backdrop, developing antibacterial synergists that enhance the activity of existing antibiotics and establishing scientific combination therapy regimens have become important strategies for addressing the drug resistance crisis. Restoring or enhancing the sensitivity of drug-resistant bacteria to antibiotics through synergists such as small-molecule metabolites helps reduce antibiotic usage, slows the evolution of resistance, and has significant practical implications for controlling drug residues and promoting the sustainable development of aquaculture.

[0005] However, the synergistic effects disclosed in existing technologies still have significant limitations. For example, a Chinese patent application discloses that α-ketoglutarate can be used in combination with kanamycin, gentamicin, streptomycin, ceftazidime, ampicillin, rifampin, or chloramphenicol to enhance bactericidal effects. However, some of the antibiotics involved in this scheme (such as chloramphenicol and rifampin) have been banned in aquaculture; some (such as kanamycin, gentamicin, and streptomycin) have shown serious resistance problems; and some (such as ceftazidime and ampicillin) have not yet been approved for use in aquaculture. Other studies have shown that components such as α-ketoglutarate and fumarate can be used in combination with antibiotics, but specific data are limited to tobramycin (which is also not approved for use in aquaculture), and the effects of different synergists vary significantly: glucose and ribose have weak synergistic effects, fructose and mannitol have no synergistic effect at all, and fumarate has the best synergistic effect. Nevertheless, it is still unclear whether these components have a general synergistic effect on other types of antibiotics.

[0006] Therefore, finding synergists that are suitable for current aquaculture standards and can effectively enhance the effects of antibiotics that are still permitted or have low resistance is of great practical significance and research value. Summary of the Invention

[0007] The technical problem to be solved by the present invention is to overcome the defects and shortcomings of existing synergist combination schemes, such as limited applicability of antibiotics, unclear synergistic effects, or lack of applicability to aquaculture. The primary objective is to provide the application of α-ketoglutarate or its pharmaceutically acceptable salt in the preparation of antibiotic synergists for aquaculture.

[0008] A second object of the present invention is to provide the use of α-ketoglutarate or a pharmaceutically acceptable salt thereof in the preparation of a medicament for enhancing the sensitivity of aquatic pathogens to antibiotics used in aquaculture.

[0009] A third object of the present invention is to provide the use of α-ketoglutarate or a pharmaceutically acceptable salt thereof in combination with antibiotics for aquaculture in the preparation of drugs against aquatic pathogens.

[0010] The fourth objective of this invention is to provide a drug for combating aquatic pathogens.

[0011] The above-mentioned objective of this invention is achieved through the following technical solution:

[0012] This invention protects the use of α-ketoglutarate or a pharmaceutically acceptable salt thereof in the preparation of antibiotic synergists for aquaculture, wherein the antibiotic for aquaculture is selected from florfenicol.

[0013] α-Ketoglutarate, an important organic acid with the molecular formula C5H6O5 and a relative molecular mass of 146.1, not only participates in energy supply but also has various other physiological functions. In aquaculture, it is widely used as a feed additive due to its ability to increase growth hormone levels, promote protein synthesis, and accelerate muscle and bone development. Studies have shown that α-ketoglutarate can significantly improve the growth performance of fish and greatly increase aquaculture efficiency. Therefore, α-ketoglutarate has high safety and promising application prospects in aquaculture. The inventors' team has discovered for the first time that adding α-ketoglutarate can increase the sensitivity of aquatic pathogens such as carbapenem-resistant Vibrio alginolyticus (CRVA) to florfenicol, exhibiting a synergistic bactericidal effect. This significantly improves the survival rate of aquatic organisms infected with CRVA, including fish, and significantly reduces the number of bacteria in the liver and spleen, alleviating damage to the organs and tissues of fish and other aquatic organisms.

[0014] Furthermore, the α-ketoglutaric acid or a pharmaceutically acceptable salt thereof enhances the susceptibility of aquatic pathogens to florfenicol.

[0015] Furthermore, the α-ketoglutaric acid or a pharmaceutically acceptable salt thereof can be used as an antibiotic synergist for aquaculture to enhance the ability of florfenicol to kill aquatic pathogens.

[0016] Furthermore, the α-ketoglutarate or a pharmaceutically acceptable salt thereof can be used as an antibiotic synergist for aquaculture to enhance the ability of florfenicol to eliminate aquatic pathogens.

[0017] Furthermore, the α-ketoglutarate or its pharmaceutically acceptable salt can be used as an antibiotic synergist in aquaculture to enhance the body's resistance to infection with aquatic pathogens.

[0018] This invention protects the use of α-ketoglutarate or a pharmaceutically acceptable salt thereof in the preparation of a medicament for enhancing the sensitivity of aquatic pathogens to antibiotics used in aquaculture, wherein the antibiotics used in aquaculture are selected from florfenicol.

[0019] This invention protects the use of α-ketoglutarate or a pharmaceutically acceptable salt thereof in combination with an aquaculture antibiotic in the preparation of an anti-aquatic pathogen drug, wherein the aquaculture antibiotic is selected from florfenicol.

[0020] Furthermore, the aquatic pathogens include one or more of Vibrio alginolyticus, Vibrio paraalginolyticus, and Aeromonas hydrophila.

[0021] Furthermore, the aquatic pathogens include both susceptible and drug-resistant bacteria.

[0022] Furthermore, the drug-resistant bacteria include drug-resistant Vibrio alginolyticus.

[0023] Furthermore, the drug-resistant Vibrio alginolyticus includes carbapenem-resistant Vibrio alginolyticus.

[0024] Furthermore, the application includes one or both of the following parameters: (1) The concentration of the α-ketoglutaric acid or a pharmaceutically acceptable salt thereof is ≥0.625 mM; (2) The concentration of florfenicol is ≥0.5μg / mL.

[0025] Preferably, the concentration of the α-ketoglutaric acid or a pharmaceutically acceptable salt thereof is ≥1.25 mM, and more preferably 5 mM.

[0026] Specifically, the concentration of α-ketoglutaric acid or its pharmaceutically acceptable salt can be 0.625, 1, 1.25, 2.5, 5, 10, 20, 30, 40, 100, 500, 1000 mM, or any specific point value between the above values, or any range of these values. For the sake of simplicity, not all possible point values ​​or ranges are listed here.

[0027] Preferably, the concentration of florfenicol is ≥2 μg / mL.

[0028] Specifically, the concentration of florfenicol can be 0.5, 0.8, 1, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 100 μg / mL, or any specific point value between the above values, or any range of these values. For the sake of simplicity, not all possible point values ​​or ranges are listed here.

[0029] Furthermore, when the aquatic pathogen is a drug-resistant Vibrio alginolyticus, the concentration of α-ketoglutarate or its pharmaceutically acceptable salt is ≥1.25 mM, and the concentration of florfenicol is ≥2 μg / mL.

[0030] Preferably, when the aquatic pathogen is a drug-resistant Vibrio alginolyticus, the concentration of α-ketoglutarate or its pharmaceutically acceptable salt is ≥5mM, and the concentration of florfenicol is ≥2μg / mL.

[0031] Preferably, when the aquatic pathogen is Aeromonas hydrophila or Vibrio parahaemolyticus, the concentration of α-ketoglutarate or its pharmaceutically acceptable salt is ≥5mM, and the concentration of florfenicol is ≥20μg / mL.

[0032] This invention protects an anti-aquatic pathogen drug, wherein the active ingredient of the anti-aquatic pathogen drug comprises α-ketoglutarate or a pharmaceutically acceptable salt thereof and florfenicol.

[0033] Furthermore, the aquatic pathogens include one or more of Vibrio alginolyticus, Vibrio paraalginolyticus, and Aeromonas hydrophila.

[0034] Furthermore, the aquatic pathogens include both susceptible and drug-resistant bacteria.

[0035] Furthermore, the drug-resistant bacteria include drug-resistant Vibrio alginolyticus.

[0036] Furthermore, the drug-resistant Vibrio alginolyticus includes carbapenem-resistant Vibrio alginolyticus.

[0037] Furthermore, the anti-aquatic pathogen drug includes one or two of the following parameters: (1) The concentration of the α-ketoglutaric acid or a pharmaceutically acceptable salt thereof is ≥0.625 mM; (2) The concentration of florfenicol is ≥0.5μg / mL.

[0038] Preferably, the concentration of the α-ketoglutaric acid or its pharmaceutically acceptable salt is ≥1.25 mM, and more preferably 5 mM.

[0039] Specifically, the concentration of α-ketoglutaric acid or its pharmaceutically acceptable salt can be 0.625, 1, 1.25, 2.5, 5, 10, 20, 30, 40, 100, 500, 1000 mM, or any specific point value between the above values, or any range of these values. For the sake of simplicity, not all possible point values ​​or ranges are listed here.

[0040] Preferably, the concentration of florfenicol is ≥2 μg / mL.

[0041] Specifically, the concentration of florfenicol can be 0.5, 0.8, 1, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 100 μg / mL, or any specific point value between the above values, or any range of these values. For the sake of simplicity, not all possible point values ​​or ranges are listed here.

[0042] Furthermore, when the aquatic pathogen is a drug-resistant Vibrio alginolyticus, the concentration of α-ketoglutarate or its pharmaceutically acceptable salt is ≥1.25 mM, and the concentration of florfenicol is ≥2 μg / mL.

[0043] Preferably, when the aquatic pathogen is a drug-resistant Vibrio alginolyticus, the concentration of α-ketoglutarate or its pharmaceutically acceptable salt is ≥5mM, and the concentration of florfenicol is ≥2μg / mL.

[0044] Preferably, when the aquatic pathogen is Aeromonas hydrophila or Vibrio parahaemolyticus, the concentration of α-ketoglutarate or its pharmaceutically acceptable salt is ≥5mM, and the concentration of florfenicol is ≥20μg / mL.

[0045] Furthermore, the duration of action of the α-ketoglutaric acid or its pharmaceutically acceptable salt in combination with florfenicol is ≥0.5h, preferably ≥2h, more preferably ≥6h, and even more preferably ≥8h.

[0046] Specifically, the duration of action of the α-ketoglutaric acid or its pharmaceutically acceptable salt in combination with florfenicol can be 0.5, 0.8, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20 hours, or any specific point value between the above values, or any range of these values. For the sake of simplicity, not all possible point values ​​or ranges are listed here.

[0047] Furthermore, the target of the anti-aquatic pathogen drug is aquatic organisms.

[0048] Preferably, the aquatic organisms include fish, crustaceans, mollusks, etc.

[0049] As an optional implementation, the fish species include tilapia.

[0050] Preferably, the crustaceans include shrimp, crab, etc.

[0051] Preferably, the molluscs includes clams, etc.

[0052] Furthermore, as an optional implementation, when the target of the anti-aquatic pathogen drug is fish, the method of administration of the anti-aquatic pathogen drug is injection.

[0053] Furthermore, the biological concentration of α-ketoglutarate or its pharmaceutically acceptable salt in the anti-aquatic pathogen drug is ≥5 mg / kg, preferably ≥10 mg / kg. This concentration can be adjusted flexibly according to actual conditions.

[0054] Furthermore, the biological concentration of florfenicol in the anti-aquatic pathogen drug is ≥20 mg / kg, preferably ≥30 mg / kg. This concentration can be adjusted flexibly according to actual conditions.

[0055] Compared with the prior art, the present invention has the following beneficial effects: This invention is the first to discover that α-ketoglutaric acid can significantly enhance the bactericidal effect of florfenicol against aquatic pathogens. Combined injection of α-ketoglutaric acid and florfenicol can reduce the number of bacteria in the liver and spleen of aquatic organisms, including fish, infected with aquatic pathogens, thus mitigating damage to the organs and tissues of fish and other aquatic organisms and improving their survival rate. Therefore, α-ketoglutaric acid can be used as a synergist for florfenicol. Its combined application in the preparation of compound antibacterial agents can improve the efficacy of aquatic antibacterial drugs, significantly reduce the dosage of antibacterial drugs, and consequently reduce side effects and drug residues. This has significant application value and importance in the production and development of drugs against aquatic pathogens. Attached Figure Description

[0056] Figure 1 A statistical graph showing the MIC determination data of imipenem for sensitive Vibrio alginolyticus and carbapenem-resistant Vibrio alginolyticus (CRVA).

[0057] Figure 2 Statistical graphs show the data on how α-ketoglutarate can enhance the susceptibility of Vibrio alginolyticus (CRVA) to florfenicol. Graph A shows the data on different concentrations of α-ketoglutarate combined with florfenicol, and Graph B shows the data on α-ketoglutarate combined with florfenicol at different treatment times.

[0058] Figure 3 The graphs are statistical charts for evaluating the combined effects of substances and antibiotics using the checkerboard method. Figure A shows the effect of α-ketoglutarate combined with florfenicol; Figure B shows the effect of α-ketoglutarate combined with chloramphenicol; and Figure C shows the effect of fumaric acid combined with florfenicol.

[0059] Figure 4 Statistical chart showing the bactericidal effects of α-ketoglutarate combined with florfenicol against different aquatic pathogens.

[0060] Figure 5 The graph shows the statistical data on how α-ketoglutarate can improve the clearance rate of florfenicol against CRVA-infected fish in the liver (A) and spleen (B) and reduce liver (C) and spleen (D) damage.

[0061] Figure 6 This is a statistical chart showing the data on how α-ketoglutarate combined with florfenicol can improve the survival rate of mice infected with Vibrio alginolyticus CRVA. Detailed Implementation

[0062] The present invention will be further described below with reference to the accompanying drawings and specific embodiments, but the embodiments do not limit the present invention in any way. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in this technical field.

[0063] Unless otherwise specified, all reagents and materials used in the following examples are commercially available.

[0064] Figure 2 A represents Figure 2 Figure A in the text, Figure 5 AB represents Figure 5 The names of the figures in the diagram are A and B, and the names of the other figures follow the same pattern.

[0065] Example 1: Preparation of Test Samples 1. In vitro experimental methods for bacterial culture and survival rate A single colony of *Vibrio alginolyticus* ATCC33787 was picked from a solid agar plate and inoculated into 5 mL of LB liquid medium (1 L contains 30 g sodium chloride, 10 g bacteriological peptone, and 5 g yeast extract). The medium was incubated at 30 °C and 220 rpm with shaking for 12 hours until saturation, then used for subculturing. The saturated culture was collected overnight, centrifuged at 8000 rpm for 3 min to collect the cells, the supernatant was removed, and the cells were washed three times with sterile 0.85% physiological saline. The culture was then adjusted to OD using M9 basal medium (1 L of solution A contains 17.1 g disodium hydrogen phosphate dodecahydrate, 3 g potassium dihydrogen phosphate, 1 g ammonium chloride, and 0.5 g sodium chloride; 5 mL of 2 M sodium acetate, 2 mL of 1 M magnesium sulfate, and 100 μL of 1 M calcium chloride were added to 1 L of solution A). 600 Adjust the value to 0.2, then dispense 5 mL into test tubes for later use.

[0066] 2. Construction of carbapenem-resistant Vibrio alginolyticus strains resistant to imipenem. A single colony of Vibrio alginolyticus ATCC33787 (sensitive bacterium) was picked from a solid agar plate and cultured in liquid medium until saturation. Then, it was transferred to 5 mL of LB medium at a 1:100 dilution and cultured until the logarithmic growth phase (OD200). 600 =0.5), the bacterial culture was mixed into a 96-well plate containing serially diluted imipenem antibiotic medium, and incubated at 30°C for 12 hours. Bacterial growth was observed, and the concentration at which colonies were not visible to the naked eye was taken as the minimum inhibitory concentration (MIC) of the antibiotic used. Based on the MIC value of the original bacteria (0.75 μg / mL), the saturated bacteria were transferred to a medium containing 1 / 2 MIC carbapenem antibiotic imipenem, and cultured at 30°C with shaking for 12 hours. The bacterial culture was collected as the first generation. The first generation was passaged, and the above steps were repeated to obtain the second generation, and so on, to obtain the passaged resistant strain (CRVA). Finally, a passaged resistant strain with a MIC of 64 times (48 μg / mL) was obtained. Figure 1 The passaged drug-resistant bacteria were stored at -80°C for subsequent experiments.

[0067] Example 2: α-Ketoglutaric acid enhances the sensitivity of CRVA to florfenicol. 1. The sensitivity of CRVA to florfenicol increases with increasing α-ketoglutaric acid concentration within a certain range. In Example 1, the CRVA bacterial culture samples prepared using M9 basal medium were first treated with florfenicol at a final concentration of 2 μg / mL, followed by the addition of α-ketoglutarate to final concentrations of 0, 1.25, 2.5, 5, 10, and 20 mM. The samples were incubated at 37°C and 220 rpm for 6 hours. The solutions were then serially diluted with 3% physiological saline to appropriate concentrations. After thorough mixing, 10 μL of the diluted solution was added dropwise to LB agar plates. After 12 hours of incubation, the viable cell count was recorded, and the survival rate was calculated. The survival rate was calculated as (viable cell count in different treatment groups / viable cell count in the control group) × 100%. The results are as follows: Figure 2 As shown in Figure A, without the addition of α-ketoglutarate, florfenicol treatment alone had little impact on bacterial survival, with a survival rate of approximately 72%. However, with the addition of α-ketoglutarate, even at a low concentration (1.25 mM), the survival rate of CRVA decreased significantly, reaching only 1.69%. As the concentration of α-ketoglutarate increased, CRVA became increasingly sensitive to antibiotics. At a concentration of 5 mM, the combined bactericidal effect was the best, showing a 150-fold increase compared to florfenicol treatment alone. At concentrations of 10 and 20 mM, the bactericidal effect remained at a certain level and did not increase further with increasing concentration. These results indicate that α-ketoglutarate can improve the sensitivity of CRVA to florfenicol, exhibiting a concentration gradient effect within a certain concentration range, with the 5 mM concentration showing the best effect.

[0068] 2. The increased sensitivity of CRVA to florfenicol is correlated with the duration of α-ketoglutaric acid treatment. To further investigate the relationship between the synergistic bactericidal effect of α-ketoglutarate and florfenicol and time, four experimental groups were set up: a control group (no florfenicol or α-ketoglutarate), a 2 μg / mL florfenicol-only group, a 5 mM α-ketoglutarate-only group, and a combined group. The cultures were incubated at 37℃ and 220 rpm for 10 hours. Every 2 hours, 100 μL of bacterial suspension was serially diluted, and 10 μL of the diluted solution was added to LB agar plates. After overnight incubation for 12 hours, the survival rate at different time points was calculated. The survival rate was calculated as (number of viable bacteria in each experimental group at a certain time point / number of viable bacteria in the control group at the corresponding time point) × 100%. The results are as follows: Figure 2As shown in Figure B, after 2 hours of treatment, the survival rate of bacteria in the single antibiotic group was 88.6%, while the survival rate in the combined group decreased to 6%, and continued to decline with increasing α-ketoglutarate treatment time. After 8 hours of treatment, the bactericidal multiple of the combined group was approximately 135 times higher than that of the florfenicol-only group, showing the best bactericidal effect. At 10 hours, the bacterial survival rate was only 0.42%, and the bactericidal multiple was still 135 times higher than that of the florfenicol-only group, indicating that the bactericidal multiple of the combined drugs tended to stabilize. These results indicate that α-ketoglutarate can improve the sensitivity of CRVA to florfenicol, and within a certain time range (0-8 hours), the longer the treatment time, the more significant the effect, with the bactericidal multiple stabilizing at 10 hours.

[0069] Example 3: α-Ketoglutarate enhances the sensitivity of pathogens to different antibiotics. 100 μL of MHB broth was added sequentially to each well of a 96-well plate. In the last row, 100 μL of α-ketoglutarate solution with a 40 mM concentration gradient was added to each well. This was serially diluted from the eighth row to the second row, with α-ketoglutarate concentrations of 40, 20, 10, 5, 2.5, 1.25, and 0.625 mM. In the eighth column, 100 μL of antibiotic stock solution was added to each well, serially diluted to the second column. Afterward, 100 μL of a 1 x 10⁻⁶ bacterial culture solution was added to each well. 6 After incubating a bacterial suspension at CFU / mL at 30°C for 12 or 24 hours, the OD of each culture well was measured. 600 Absorbance values ​​were used to generate bacterial calorimetry using Gradprism 8.0 software, and the fractional inhibitory concentration (FIC) index was calculated for the combined use of the two antibiotics. The formula is: FIC = MIC (A combined use) / MIC (A alone) + MIC (B combined use) / MIC (B alone); where A is an antibiotic (florfenicol or chloramphenicol), and B is α-ketoglutarate or fumarate. The FIC index interpretation criteria are as follows: when the FIC index is less than 0.5, the two drugs have a synergistic effect; when the FIC index is between 0.5 and 1, the two drugs have an additive effect; when the FIC index is greater than 1 and less than 2, the two drugs have no effect; and when the FIC index is greater than 2, the two drugs have an antagonistic effect.

[0070] The experimental results are shown in Figure 3 The FIC value was calculated to be 0.126, indicating that the combined use of α-ketoglutarate and florfenicol has a synergistic effect against imipenem-resistant Vibrio alginolyticus ATCC33787 (CRVA). Figure 3 A); FIC=0.8125, indicating that the combined use of α-ketoglutarate and chloramphenicol has an additive effect on imipenem-resistant Vibrio alginolyticus ATCC33787 (CRVA). Figure 3B), no synergistic effect; FIC=1, indicating that the combined use of fumaric acid and florfenicol has an additive effect on imipenem-resistant Vibrio alginolyticus ATCC33787 (CRVA). Figure 3 C), there is no synergistic effect. Therefore, α-ketoglutaric acid can greatly enhance the bactericidal effect of florfenicol against aquatic pathogens, exhibiting a significant synergistic antibacterial effect.

[0071] Example 4: α-Ketoglutaric acid enhances the susceptibility of florfenicol to different aquatic pathogens. Select aquatic pathogens isolated from the environment, such as Vibrio parahaemolyticus (V. parahaemolyticus). VP -14 and VP -31) Single colonies were inoculated into 5 mL of 3% LB liquid medium (1 L contains 30 g sodium chloride, 10 g bacteriological peptone, and 5 g yeast extract), while Aeromonas hydrophila ATCC 7966 was inoculated into normal LB medium (1 L contains 10 g sodium chloride, 10 g bacteriological peptone, and 5 g yeast extract). The cultures were incubated at 37°C and 220 rpm for 12 hours with shaking until saturation was achieved for sterilization experiments. The saturated bacterial culture was collected overnight, centrifuged at 8000 rpm for 3 minutes to collect the cells, and the supernatant was removed. The cells were washed three times with sterile 0.85% physiological saline. Then, the OD of the bacterial culture was adjusted using M9 basal medium (1 L of solution A contains 17.1 g disodium hydrogen phosphate dodecahydrate, 3 g potassium dihydrogen phosphate, 1 g ammonium chloride, and 0.5 g sodium chloride; 5 mL of 2 M sodium acetate, 2 mL of 1 M magnesium sulfate, and 100 μL of 1 M calcium chloride must be added to 1 L of solution A). 600 The concentration was adjusted to 0.2, and 5 mL was dispensed into test tubes for later use. Subsequently, 5 mM α-ketoglutarate was added to each of the 5 mL aliquots of bacterial culture, and the concentration of florfenicol was determined according to the specific bacterial strain: Aeromonas hydrophila ATCC 7966, VP -14 and VP The treatment concentration for -31 was 20 μg / mL. After incubation at 37°C and 220 rpm for 6 hours, the treated bacterial cultures were diluted and spotted onto a plate. After overnight incubation, the number of colonies was counted to assess bacterial viability.

[0072] The results are as follows Figure 4 As shown, α-ketoglutaric acid can significantly enhance the bactericidal effect of florfenicol against various aquatic pathogens. For Aeromonas hydrophila ATCC 7966, the survival rate after 6 hours of treatment was only 1.15%, which is about 8 times higher than the bactericidal effect of florfenicol alone; for two strains of Vibrio parahaemolyticus isolated from the environment... VP -14 and VPThe survival rates after 6 hours of treatment (-31%) were 8.5% and 2.5%, respectively, representing a 6-fold and 14.7-fold increase in bactericidal efficacy compared to florfenicol alone. These results indicate that the combined use of α-ketoglutaric acid and florfenicol has a broad-spectrum bactericidal effect and can significantly improve the bactericidal efficacy of florfenicol against a variety of common aquatic pathogens. This discovery provides a new reference for developing novel antibacterial treatment regimens for aquatic organisms.

[0073] Example 5: α-Ketoglutarate increases the ability of florfenicol to clear drug-resistant bacteria in vivo and reduces damage to visceral tissues. 1. Fish infection, bacterial clearance test and H&E staining test Tilapia (32 ± 0.5 g) purchased from a tilapia farm in Guangzhou were raised in 25L tanks equipped with a closed recirculating aquaculture system for two weeks for acclimatization. 100 μL of 1.0 x 10 g nitrate was administered intraperitoneally. 9 120 tilapia were challenged with a bacterial suspension containing CFU / mL and randomly divided into four groups of 30 fish each. Except for the normal control group (injected with 100 μL PBS), the other three groups were injected with 100 μL α-ketoglutarate (10 mg / kg), 100 μL florfenicol (30 mg / kg), and 100 μL α-ketoglutarate + florfenicol (both α-ketoglutarate and florfenicol were prepared with PBS), respectively. Liver and spleen tissues were collected after 12 hours, and the tissue weight was recorded. For every 10 mg of tissue, 1 mL of pre-cooled PBS was added, and the mixture was homogenized using a tissue homogenizer. After serial dilution, the same bacterial suspension was cultured on LB agar plates at 30 °C for 12 hours. The bacterial count was then calculated to determine the effectiveness of α-ketoglutarate combined with florfenicol in eliminating drug-resistant bacteria in fish. Meanwhile, the liver and spleen were removed, fixed, dehydrated, embedded, and sectioned. Hematoxylin and eosin (H&E) staining was performed, and photographs were taken under an optical microscope to observe the damage and protection of the organs and tissues. A normal group, i.e., tilapia not infected with CRVA, was also included.

[0074] 2. Experimental Results Bacterial count results showed that α-ketoglutarate alone had little effect on clearing pathogens from the fish, including those in the liver. Figure 5 A) and spleen tissue ( Figure 5 B). However, florfenicol alone showed some clearance effect, reducing bacterial counts by 4-fold and 4.6-fold, respectively, compared to the control group. The treatment group using α-ketoglutarate and florfenicol in combination showed the most significant effect, reducing bacterial counts by 88-fold and 37.8-fold, respectively, compared to the control group. Compared to the treatment group using florfenicol alone, the combination therapy group reduced bacterial counts by 21.8-fold and 8.2-fold, significantly improving the treatment effect. Figure 5 AB).

[0075] Furthermore, the treatment effect was assessed by hematoxylin and eosin (H&E) staining of sections. Results showed that the cells in the normal group (uninfected group) had normal morphology and were tightly packed; while the cells in the infected group generally exhibited severe vacuolation. The improvement in cell morphology was poor with either α-ketoglutarate or florfenicol alone, while the best improvement was observed with the combined use of α-ketoglutarate and florfenicol, approaching the level of the normal group. Figure 5 CD).

[0076] Example 6: α-Ketoglutarate combined with florfenicol can improve the survival rate of CRVA-infected tilapia. To investigate whether α-ketoglutarate combined with florfenicol could improve the survival rate of tilapia infected with CRVA, the experiment used intraperitoneal injection of 100 μL of 1.0 x 10⁻⁶ florfenicol. 9 A CRVA infection model was constructed in tilapia using a bacterial suspension of CFU / mL. Drug treatment began 12 hours after infection. The experiment was divided into four groups: except for the challenge group (100 μL PBS prepared with 1.0 x 10⁻⁶ CFU / mL),... 9 The first group was treated with CFU / mL bacterial suspension. The other three groups were injected with 100 μL of α-ketoglutarate (10 mg / kg), 100 μL of florfenicol (30 mg / kg), and 100 μL of α-ketoglutarate + florfenicol (both α-ketoglutarate and florfenicol were prepared with PBS), respectively, with 30 fish in each group. The survival status and mortality rate of the fish were monitored daily for 7 consecutive days. The survival rate of tilapia was calculated as (number of surviving tilapia in different treatment groups / number of tilapia in the control PBS treatment group) × 100%. The results showed that all tilapia infected with CRVA died within 24 hours, and all tilapia in the α-ketoglutarate group died within 48 hours. The survival rate of tilapia in the florfenicol group continued to decline from 0 to 4 days, reaching 10% on the 4th day and then stabilizing. The survival rate of the α-ketoglutarate combined with florfenicol group also declined from 0 to 3 days, but the decline was the slowest, reaching 56% on the 3rd day and then stabilizing. On day 7, the survival rate in the combination group was 5.6 times higher than that in the florfenicol monotherapy group. Figure 6 These results indicate that the combined treatment group significantly improved the survival rate of tilapia.

[0077] The above embodiments are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above embodiments. Any changes, modifications, substitutions, combinations, or simplifications made without departing from the spirit and principle of the present invention shall be considered equivalent substitutions and shall be included within the protection scope of the present invention.

Claims

1. The use of α-ketoglutaric acid or a pharmaceutically acceptable salt thereof in the preparation of antibiotic synergists for aquaculture, characterized in that, The antibiotic used in aquaculture is selected from florfenicol.

2. The use of α-ketoglutaric acid or a pharmaceutically acceptable salt thereof in the preparation of drugs for enhancing the sensitivity of aquatic pathogens to antibiotics used in aquaculture, characterized in that, The antibiotic used in aquaculture is selected from florfenicol.

3. The use of α-ketoglutaric acid or a pharmaceutically acceptable salt thereof in combination with antibiotics for aquaculture in the preparation of drugs against aquatic pathogens, characterized in that, The antibiotic used in aquaculture is selected from florfenicol.

4. The application according to any one of claims 1 to 3, characterized in that, The application includes one or both of the following parameters: (1) The concentration of the α-ketoglutaric acid or a pharmaceutically acceptable salt thereof is ≥0.625 mM; (2) The concentration of florfenicol is ≥0.5μg / mL.

5. The application according to claim 2 or 3, characterized in that, The aquatic pathogens include one or more of Vibrio alginolyticus, Vibrio paraalginolyticus, and Aeromonas hydrophila.

6. The application according to claim 2 or 3, characterized in that, The aquatic pathogens include both susceptible and drug-resistant bacteria.

7. A drug for treating aquatic pathogens, characterized in that, The active ingredients of the anti-aquatic pathogen drug include α-ketoglutarate or a pharmaceutically acceptable salt thereof and florfenicol.

8. The anti-aquatic pathogen drug according to claim 7, characterized in that, The aquatic pathogens include one or more of Vibrio alginolyticus, Vibrio paraalginolyticus, and Aeromonas hydrophila.

9. The anti-aquatic pathogen drug according to claim 7, characterized in that, The aquatic pathogens include both susceptible and drug-resistant bacteria.

10. The anti-aquatic pathogen drug according to claim 7, characterized in that, The anti-aquatic pathogen drug includes one or two of the following parameters: (1) The concentration of the α-ketoglutaric acid or a pharmaceutically acceptable salt thereof is ≥0.625 mM; (2) The concentration of florfenicol is ≥0.5μg / mL.